This SS-31 dosing protocol guide explains typical research amounts, reconstitution steps, and safety notes for the mitochondrial peptide in studies.
SS-31, also known as elamipretide, is a mitochondria-targeted tetrapeptide, and there is no single FDA-approved SS-31 dosing protocol for human use in the United States. In published human trials, it has most often been given as a once-daily subcutaneous injection of 0.05 to 0.25 mg/kg, while several later studies used a flat 40 mg daily dose. Animal research typically uses 1 to 5 mg/kg per day.
That range is wide because dose depends on the model, the route of administration, and the endpoint being measured. The sections below summarize what has actually been reported, along with the reconstitution math researchers use to prepare lyophilized vials.
What Is SS-31 and What Does Research Show?
SS-31 is a synthetic tetrapeptide designed to concentrate in the inner mitochondrial membrane. It binds cardiolipin, a phospholipid that keeps mitochondrial cristae organized and supports efficient electron transport.
Research into ss-31 benefits centers on cellular energy metabolism, oxidative stress, and muscle performance rather than on curing any specific disease. Preclinical work has explored heart failure, kidney injury, and skeletal muscle function, and human trials have focused on rare mitochondrial disorders.
SS-31 is a research chemical. It is not FDA-approved for any human indication, and it is not a dietary supplement.
SS-31 Dosing Protocol Reported in Published Studies
The table below summarizes doses reported in peer-reviewed literature. These figures describe research settings only and are not a treatment recommendation.
| Research setting | Route | Reported dose | Frequency |
|---|---|---|---|
| Early human pharmacokinetic studies | Subcutaneous | 0.05–0.25 mg/kg | Once daily |
| Barth syndrome trials | Subcutaneous | 40 mg flat dose | Once daily |
| Heart failure infusion studies | IV infusion | 0.05 mg/kg/hr over 4 hours | Short infusions |
| Rodent studies | Subcutaneous or intraperitoneal | 1–5 mg/kg | Once daily |
| Cell culture | In vitro | 10 nM–10 µM | Continuous exposure |
Two practical points follow from this table. Doses used in rodent studies cannot be converted directly into human doses without allometric scaling, and subcutaneous elamipretide has been used far more often in human trials than oral forms.
Study duration also matters, because most human trials ran for 4 to 12 weeks. No long-term dosing data exist for SS-31.
Reconstitution and Concentration Math
The ss-31 reconstitution and dosage steps below are standard laboratory procedures for lyophilized peptide vials. Vials usually ship as a powder and must be dissolved before use.
- Let the vial reach room temperature and wipe the rubber stopper with an alcohol swab.
- Inject bacteriostatic water or sterile saline slowly down the inside wall of the vial rather than onto the powder directly.
- Swirl gently until the powder dissolves completely. Do not shake, because shaking can damage the peptide.
- Label the vial with the concentration, the diluent used, and the date of mixing.
- Refrigerate at 2–8 °C and protect the solution from light.
A common mistake in ss-31 peptide dosing is confusing milligrams per milliliter with milligrams per kilogram. Concentration tells you how much peptide is in each milliliter of solution, while a body-weight dose tells you how many milligrams a subject receives per kilogram.
| Vial size | Bacteriostatic water added | Final concentration | Volume per 1 mg |
|---|---|---|---|
| 5 mg | 2.5 mL | 2 mg/mL | 0.5 mL |
| 10 mg | 5 mL | 2 mg/mL | 0.5 mL |
| 10 mg | 2 mL | 5 mg/mL | 0.2 mL |
| 50 mg | 5 mL | 10 mg/mL | 0.1 mL |
Concentrations above 10 mg/mL can be difficult to dissolve completely, so most labs stay at or below that level.
SS-31 and MOTS-c Together in Research
MOTS-c is a 16-amino-acid mitochondrial-derived peptide studied for metabolic and exercise-related effects. Researchers who examine ss-31 and mots-c together usually do so because the two act on different parts of mitochondrial signaling: SS-31 targets membrane cardiolipin, while MOTS-c influences AMPK-related metabolic pathways.
No published human trial has tested the combination, so any stacking schedule that circulates online is speculative. There is no evidence that combining the two improves outcomes in humans.
In animal work, the peptides are typically studied in separate groups rather than in the same subject, which makes interaction data hard to find.
Reported SS-31 Side Effects
In completed human trials, the most commonly reported ss-31 side effects were mild injection-site reactions such as redness, tenderness, and swelling. Headache, nausea, and dizziness were also reported, generally at rates similar to placebo.
Serious adverse events were uncommon in the Barth syndrome and primary mitochondrial myopathy trials, but those studies were small and short. Whether side effects differ with long-term or higher-dose use in humans is unknown.
The FDA declined to approve elamipretide for Barth syndrome in 2022, and SS-31 remains an investigational compound rather than an approved therapy.
Storage, Handling, and Legal Status
Lyophilized SS-31 should be stored refrigerated at 2–8 °C, protected from light, and kept sealed until reconstitution. Reconstituted solutions are usually used within a few weeks and refrigerated between uses.
Vendors that supply research peptides often include a certificate of analysis showing HPLC purity and mass spectrometry confirmation. Purity above 98% is the usual benchmark researchers look for.
Products labeled “for laboratory research use only” are not intended for human consumption, and purchasing them does not make human use legal. Anyone considering SS-31 for personal use should speak with a licensed healthcare professional, because self-dosing an unapproved peptide carries real risk.
Frequently Asked Questions
What is the typical SS-31 dosing protocol used in human studies?
In published human trials, SS-31 has most often been given once daily by subcutaneous injection at 0.05 to 0.25 mg/kg, and some later trials used a flat 40 mg dose. These figures describe research settings only, because no SS-31 protocol has been approved by the FDA for human use.
How much bacteriostatic water do you add to a 10 mg SS-31 vial?
Adding 2 mL of bacteriostatic water to a 10 mg vial produces a 5 mg/mL solution, while adding 5 mL produces a 2 mg/mL solution. The right choice depends on how precisely your syringe can measure the volume you need.
Is SS-31 safe to use?
SS-31 is not FDA-approved for human use, and there is no long-term human safety data. Reported side effects in trials include injection-site reactions, headache, nausea, and dizziness. Anyone considering it should consult a licensed healthcare professional first.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.